Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes

Hepatology

Volumn 27, Issue 6, 1998, Pages 1687-1694

  Ilyin, Gennady P ^a   Langouët, Sophie ^b   Rissel, Maryvonne ^b   Üelcros, Jean Guy ^c   Guillouzo, Andre ^b   Guguen Guillouzo, Christiane ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CELL CYCLE PROTEIN; CYCLIN A; GUANOSINE DERIVATIVE; HAPTOGLOBIN; MITOGENIC AGENT; MYCOPHENOLIC ACID; PROTEIN; RECOMBINANT EPIDERMAL GROWTH FACTOR; RIBAVIRIN; SCATTER FACTOR;

ANIMAL CELL; ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT;

ANIMALS; ANTIMETABOLITES; ANTIVIRAL AGENTS; CELL DIVISION; CELLS, CULTURED; DRUG ANTAGONISM; EPIDERMAL GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER; MALE; PROTEIN BIOSYNTHESIS; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN;

EID: 0031779757     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270630     Document Type: Article

References (29)

1. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997;53:74-85.
2. Sidwell R, Huffman JH, Khare L, Allen LB, Witlowski JT, Robins RK. Broad-spectrum activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;117:705-706.
3. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hep 1996;3:247-252.
4. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598.
5. Schvarcz R, Yun ZB, Sonnenborg A, Weiland O. Combined treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to Interferon alone. J Med Virol 1995;46:43-47.
6. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
7. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966.
8. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174-1178.
9. Yamada Y, Natsumcda Y, Weber G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 1988;27:2193-2196.
10. Peavy DL, Koff WC, Hyman DS, Knight V Inhibition of lymphocyte proliferative responses by ribavirin. Infect Immun 1980;29:583-589.
11. Lee H-J, Pawlak K, Nguyen BT, Robins RK, Sadée W. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 1985;45:5512-5520.
12. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991;87:1916-1924.
13. Guguen-Guillouzo C, Campion J-P, Brissot P, Glaise D, Launois B, Bourel M, Guillouzo A. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol Int Rep 1982;6:625-628.
14. Guguen C, Gregori C, Schapira E Modification of pyruvate kinase isozymes in prolonged primary culture of adult rat hepatocytes. Biochimie 1975;9:1065-1071.
15. Loyer P, Ilyin G, Abdel-Razzak Z, Banchereau J, Dezier J-F, Campion J-P, Guguen-Guillouzo C, et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993;336:215-220.
16. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitotic signals. Cell 1994;78:59-66.
17. 1. J Biol Chem 1996;271:11484-11892.
18. Drach JC, Thomas MA, Barnett JW, Smith SH, Shipman C. Tritiated thymidine incorporation does not measure DNA synthesis in ribavirintreated human cells. Science (Wash. DC) 1981;212:549-551.
19. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:936-947.
20. Guillén MI, Gomez-Lechon MJ, Nakamura T, Castell JV. The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: Divergent effect on interleukin-6-slimulated genes. HEPATOLOGY 1996;23:1345-1352.
21. Blanc P, Etienne H, Daujat M, Fahre I, Zindy F, Domergue J, Astre C, et al. Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor α , and human serum. Gastroenterology 1992;102:1340-1350.
22. Ismail T, Howl J, Wheatley M, McMaster P, Neuberger JM, Strain AJ. Growth of normal human hepatocytes in primary culture: effects of hormones and growth factors on DNA synthesis. HEPATOLOGY 1991;14:1076-1082.
23. Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N, Daikuhara Y, et al. Native and recombinant human hepatocyte growth factors are highly potent promotors of DNA synthesis of both human and rat hepatocytes. J Clin Invest 1991;87:1853-1857.
24. Gomez-Lechon MJ, Castelli J, Guillén I, O'Connor E, Nakamura T, Fabra R, Trullenque R. Effect of hepatocyte growth factor on the growth and metabolism of human hepatocytes in primary culture. HEPATOLOGY 1995;21:1248-1254.
25. Connor JD, Hintz M, Van Dyke R, McCormick JB, McIntosh K. Ribavirin pharmacokinetics in children and adults during therapeutic trials. In: Smith RA, Knight V, Smith JAD, eds. Clinical Applications of Ribavirin. Orlando: Academic Press, 1984:107-123.
26. Roberts RB, Laskin OL, Laurence J, Scavuzzo D, Murray HW, Kim YT, Connor JD. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987;42:365-373.
27. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993;37:532-539.
28. Shulman NR. Assessment of hematologic effects of ribavirin in humans. In: Smith RA, Knight V, Smith JAD, eds. Clinical Applications of Ribavirin. Orlando: Academic Press, 1984:79-91.
29. Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991;50:442-449.